Quest Diagnostics introduces opioid therapy genetic test

Aug. 15, 2013

Quest Diagnostics has announced the availability of a new lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It offers testing for variants in all cytochrome P450 (CYP450) genes known to influence the CYP450 enzyme system, which affects metabolism of opioids and other medications.

The test is based in part on gene variants owned by Transgenomic, Inc., through a non-exclusive licensing agreement between the two companies. Quest developed, validated, and now offers the test service through its advanced Nichols Institute facility in San Juan Capistrano, CA.

Research demonstrates that genetic testing to identify gene variants that mediate the CYP450 enzyme system can help physicians predict the rate of opioid drug metabolism. With this information, they can decide to adjust doses or administer other therapies in order to improve the prospect for effective pain relief and reduce the likelihood of drug toxicity, drug interactions, and other adverse outcomes.

“Genetic testing to personalize the use of pain-alleviating drug therapies is an exciting new clinical field with tremendous potential to promote favorable outcomes for the many millions of individuals struggling with pain,” says Charles Strom, MD, PhD, Senior Medical Director, Genetics, Quest Diagnostics. “Opioids can be very effective pain-alleviating medications, but they are also powerful and potentially dangerous drugs carrying a high risk of addiction, toxicity, and other adverse effects. The inclusion of Transgenomic’s gene discoveries into our genetic testing services will provide physicians with greater insights for safely and effectively administering opioid treatment.” Learn more about genetic testing solutions offered by Quest.